Real-World study reveals how breast cancer drug palbociclib is used in israel

NCT ID NCT04671615

Completed Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at 559 adults in Israel with metastatic breast cancer who were prescribed palbociclib (Ibrance) as part of their treatment. Researchers tracked how the drug was used in everyday practice, including doses, combinations with other treatments, and how long patients stayed on therapy. The goal was to understand real-world treatment patterns and outcomes over about 3.5 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: palbociclib (Ibrance)
What this could lead to: If successful, this study could help doctors understand how palbociclib is actually used in real-world settings, potentially improving treatment guidelines for metastatic breast cancer.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other countries or healthcare systems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BREAST CANCER

Contacts and locations

Locations

Pfizer Pharmaceuticals Israel Ltd.

Herzliya Pituah, 4672509, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.